Skip to main content

Table 5 Comparison of baseline patient characteristics, treatment outcomes and selected toxicity profiles after afatinib as 2nd TKI therapy in LUX-Lung1 and current study

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

  LUX-Lung1 study Current study
Number of patients 390 25
Age (range) 58 (30–85) 63 (42–85)
Male/female (%) 159 (40.8)/231 (59.2) 11 (44.0)/14 (56.0)
ECOG performance status (%)   
  0 92 (23.6) 1 (4.0)
  1 268 (68.7) 12 (48.0)
  2 30 (7.7) 12 (48.0)
Prior EGFR-TKI therapy (%)   
  Erlotinib 215 (55.1) 14 (56.0)
  Gefitinib 152 (39.0) 11 (44.0)
  Both 23 (5.9) 0 (0)
Number of lines of prior chemotherapy (%)   
  1 231 (59.2) 14 (56)
  2 156 (40.0) 11 (44)
  3 3 (0.8) 0 (0)
Objective response (%)   
  Partial response 29 (7.4) 5 (20.0)
  Stable disease 198 (50.8) 12 (48.0)
Disease control (%) 227 (58.2) 17 (68.0)
Median progression-free survival in months (range) 3.3 (2.8–4.4) 4.1 (2.7–5.5)
Median overall survival in months (range) 10.8 (10.0–12.0) 10.3 (7.5–13.0)
Selected toxicity profiles (%) All grades (%) ≥Grade 3 (%) All grades (%) ≥Grade 3 (%)
  Rash 305 (78.2) 56 (14.4) 15 (60.0) 0 (0)
  Diarrhea 339 (86.9) 66 (16.9) 15 (60.0) 7 (28.0)
  Mucositis/stomatitis 237 (60.8) 12 (3.1) 1 (4.0) 0 (0)
  Paronychia/nail effect 153 (39.2) 20 (5.1) 2 (8.0) 0 (0)
  Hypokalemia 34 (8.7) 11 (2.8) 2 (8.0) 2 (8.0)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, TKI tyrosine-kinase inhibitor